We know that pharmaceuticals as an industry earn billions of dollars each year. We also know they are taking up an increasing share of annual health care spending. Part of what is driving this spending is new medication developments — every year, pharmaceutical manufactures develop hundreds of new medications. In the behavioral health market alone, there were 148 drugs in the U.S. Food and Drug Administration (FDA) pipeline in 2016. According to Pharmaceutical Research and Manufacturers of America (PhRMA), this included 14 drugs for anxiety disorders, 19 for attention-deficit/hyperactivity disorder, 10 for bipolar disorders, 29 for depression, two . . .